| Year |
Citation |
Score |
| 2018 |
Orillion AR, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti HC, Elbanna M, Chintala S, Ciesielski MJ, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia DJ, Abrams SI, et al. Dietary protein restriction reprograms tumor associated macrophages and enhances immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190370 DOI: 10.1158/1078-0432.Ccr-18-0980 |
0.333 |
|
| 2018 |
Damayanti NP, Ahmed K, Elbanna M, Kao C, Pili R. Abstract 3109: Investigating the role of wild-type TFE3 in renal cell carcinoma cells harboring TFE3 fusions with spliceosome machinery associated genes Cancer Research. 78: 3109-3109. DOI: 10.1158/1538-7445.Am2018-3109 |
0.398 |
|
| 2017 |
Orillion A, Hashimoto A, Damayanti NP, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R. Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28698201 DOI: 10.1158/1078-0432.Ccr-17-0741 |
0.392 |
|
| 2017 |
Adelaiye-Ogala RM, Chintala S, Orillion A, Elbanna M, Elzey B, Damayanti N, Miles KM, Kao C, Pettazzoni P, Draetta GF, Pili R. Abstract 4170: Targeting androgen receptor overcomes resistance to tyrosine kinase inhibitors in advanced clear cell renal cell carcinoma Cancer Research. 77: 4170-4170. DOI: 10.1158/1538-7445.Am2017-4170 |
0.313 |
|
| 2017 |
Orillion AR, Chintala S, Adelaiye-Ogala R, Shen L, Damayanti N, Elbanna M, Arisa S, Elzey B, Kao C, Fontana L, Pili R. Abstract 250: Methionine restriction increases macrophage tumoricidal activity and significantly inhibits prostate cancer growth Cancer Research. 77: 250-250. DOI: 10.1158/1538-7445.Am2017-250 |
0.493 |
|
| 2016 |
Orillion A, Adelaiye-Ogala R, Shen L, Ciamporcero E, Elbanna M, Chintala S, Arisa S, Elzey B, Kao C, Fontana L, Pili R. Abstract 897: Methionine restriction alters functional polarization of macrophages in a murine model of prostate cancer Cancer Research. 76: 897-897. DOI: 10.1158/1538-7445.Am2016-897 |
0.407 |
|
| 2016 |
Adelaiye-Ogala RM, Chintala S, Orillion A, Pettazzoni P, Elbanna M, Elzey B, Miles KM, Kao C, Draetta GF, Pili R. Abstract 2126: Androgen receptor expression is associated with sunitinib resistance in renal cell carcinoma models Cancer Research. 76: 2126-2126. DOI: 10.1158/1538-7445.Am2016-2126 |
0.371 |
|
| 2016 |
Raikwar SP, Kao CH, Gardner TA. Targeted Adenoviral Vectors III: Transcriptional Targeting Adenoviral Vectors For Gene Therapy: Second Edition. 259-292. DOI: 10.1016/B978-0-12-800276-6.00010-3 |
0.31 |
|
| 2015 |
Liu Y, Chen L, Gong Z, Shen L, Kao C, Hock JM, Sun L, Li X. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Oncotarget. 6: 3055-70. PMID 25605010 DOI: 10.18632/Oncotarget.3073 |
0.451 |
|
| 2013 |
KAMIJIMA S, KIMURA T, HAGA K, HIRAOKA K, INAGAKI A, LOGG C, KAO C, BOCHNER B, KASAHARA N. 328 PROSTATE-TARGETED RETROVIRAL REPLICATING VECTORS FOR PRODRUG-ACTIVATOR GENE THERAPY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1713 |
0.439 |
|
| 2012 |
Zhau HE, Zhao LS, Chung LW, Chen BQ, Troncoso P, Kao C, Kojima M, Fraser Symmans W, Zheng N, Palmer JL, Moul JW, Davis R, Ye MF, Xiao LS, Craig Hall M. Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urologic Oncology. 1: 51-63. PMID 21224092 DOI: 10.1016/1078-1439(95)00009-7 |
0.443 |
|
| 2012 |
Cao N, Song S, Shaffer M, Maleki T, Cao M, Kao C, Stantz K, Ziaie B, Ko S. Monitoring the Radiosensitizing Effects of Implantable Micro-oxygen Generator in Pancreatic Cancer Xenografts International Journal of Radiation Oncology*Biology*Physics. 84: S699. DOI: 10.1016/J.Ijrobp.2012.07.1867 |
0.337 |
|
| 2011 |
Jiang ZK, Sato M, Wei LH, Kao C, Wu L. Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Research. 71: 6250-60. PMID 21933883 DOI: 10.1158/0008-5472.CAN-11-1520 |
0.388 |
|
| 2011 |
Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey BD, Kao C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology. 133: 221-38. PMID 21453419 DOI: 10.1111/J.1365-2567.2011.03429.X |
0.68 |
|
| 2011 |
Li Y, Sikes RA, Malaeb BS, Yeung F, Law A, Graham SE, Pei M, Kao C, Nelson J, Koeneman KS, Chung LW. Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models. Urologic Oncology. 29: 802-8. PMID 20451417 DOI: 10.1016/J.Urolonc.2009.09.016 |
0.461 |
|
| 2011 |
Kamijima S, Kimura T, Haga K, Hiraoka K, Inagaki A, Logg CR, Kao C, Bochner BH, Ichikawa T, Kasahara N. Abstract 5393: Prodrug activator gene therapy mediated by prostate-specific replicating retrovirus vectors Cancer Research. 71: 5393-5393. DOI: 10.1158/1538-7445.Am2011-5393 |
0.54 |
|
| 2010 |
Li X, Liu Y, Tang Y, Roger P, Jeng MH, Kao C. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. The Journal of Gene Medicine. 12: 516-27. PMID 20527044 DOI: 10.1002/Jgm.1462 |
0.496 |
|
| 2010 |
Jiménez JA, Li X, Zhang YP, Bae KH, Mohammadi Y, Pandya P, Kao C, Gardner TA. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL Cancer Gene Therapy. 17: 180-191. PMID 19798123 DOI: 10.1038/Cgt.2009.62 |
0.51 |
|
| 2009 |
Ahn M, Lee SJ, Li X, Jiménez JA, Zhang YP, Bae KH, Mohammadi Y, Kao C, Gardner TA. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter Cancer Gene Therapy. 16: 73-82. PMID 18772902 DOI: 10.1038/cgt.2008.59 |
0.462 |
|
| 2009 |
Kang TW, Kao M, Kao C, Gardner TA, Johnstone PA, Jung C, Ko S. USE OF LOW DOSE BEVACIZUMAB AS A POTENTIAL RADIATION SENSITIZER IN EXTERNAL BEAM RADIATION THERAPY OF CWR22RV HUMAN PROSTATE CANCER IN VIVO Journal of Urology. 181: 392-392. DOI: 10.1016/S0022-5347(09)61115-0 |
0.361 |
|
| 2009 |
Kang T, Ahn M, Johnstone P, Kao C, Ko S, Gardner T. MP-15.06: Enhancement of FCYttk-Armed Prostate-Restricted Replicative Adenovirus Effect with Prodrugs Gancyclovir and 5-FC In Prostate Cancer Urology. 74: S115. DOI: 10.1016/J.Urology.2009.07.840 |
0.457 |
|
| 2009 |
Ko S, Kang TW, Cao M, Gardner TA, Johnstone PA, Kao C. Bevacizumab as a Potential Radiation Sensitizer in External Beam Radiation Therapy of CWR22RV Human Prostate Cancer In Vivo International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.1297 |
0.379 |
|
| 2008 |
Mellon MJ, Bae KH, Steding CE, Jiménez JA, Kao C, Gardner TA. Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapy. Human Gene Therapy. 19: 487-95. PMID 18507514 DOI: 10.1089/Hum.2007.135 |
0.7 |
|
| 2008 |
Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 291-9. PMID 18172281 DOI: 10.1158/1078-0432.Ccr-07-0867 |
0.446 |
|
| 2008 |
Mellon MJ, Ahn M, Jiménez JA, Kao C, Gardner TA. Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model. The Journal of Urology. 179: 737-42. PMID 18082201 DOI: 10.1016/J.Juro.2007.09.017 |
0.406 |
|
| 2008 |
Jimenez J, Mohammadi Y, Ko S, Johnstone P, Kao C, Gardner T. Anti-tumor and Radio-sensitizing Properties of Ad-IU2, A Prostate-specific Replication-competent Adenovirus Armed with TRAIL International Journal of Radiation Oncology*Biology*Physics. 72: S76-S77. DOI: 10.1016/J.Ijrobp.2008.06.939 |
0.453 |
|
| 2007 |
Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, Sugimura K, Matsuo M, Hamada K, Fuji K, Okegawa T, Higashihara E, Gardner TA, Kao C, Chung LW, et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Human Gene Therapy. 18: 1225-32. PMID 18021019 DOI: 10.1089/Hum.2007.074 |
0.463 |
|
| 2007 |
Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Jeng MH, Kao C. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5463-73. PMID 17875776 DOI: 10.1158/1078-0432.Ccr-07-0342 |
0.501 |
|
| 2007 |
Figueiredo ML, Kao C, Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1053-64. PMID 17457317 DOI: 10.1038/Sj.Mt.6300181 |
0.402 |
|
| 2007 |
Abbosh PH, Li X, Li L, Gardner TA, Kao C, Nephew KP. A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Therapy. 14: 399-408. PMID 17218945 DOI: 10.1038/Sj.Cgt.7701024 |
0.395 |
|
| 2006 |
Jiménez JA, Kao C, Raikwar S, Gardner TA. Current status of anti-angiogenesis therapy for prostate cancer. Urologic Oncology. 24: 260-8. PMID 16678061 DOI: 10.1016/J.Urolonc.2005.11.022 |
0.473 |
|
| 2006 |
Desai P, Jiménez JA, Kao C, Gardner TA. Future innovations in treating advanced prostate cancer. The Urologic Clinics of North America. 33: 247-72, viii. PMID 16631463 DOI: 10.1016/J.Ucl.2005.12.005 |
0.468 |
|
| 2006 |
Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA, Kao C. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. The Journal of Gene Medicine. 8: 679-89. PMID 16570242 DOI: 10.1002/Jgm.904 |
0.371 |
|
| 2006 |
Li X, Raikwar SP, Liu YH, Lee SJ, Zhang YP, Zhang S, Cheng L, Lee SD, Juliar BE, Gardner TA, Jeng MH, Kao C. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Molecular Cancer Therapeutics. 5: 676-84. PMID 16546982 DOI: 10.1158/1535-7163.Mct-05-0339 |
0.524 |
|
| 2006 |
Li X, Raikwar SP, Lee S, Kim H, Zhang S, Gardner TA, Jeng M, Kao C. 806: Combination Therapy of Androgen-Independent Prostate Cancer Using a Prostate Restricted Replicative Adenovirus and a Replication Deficient Adenovirus Encoding Human Endostatin-Angiostatin Fusion Protein Journal of Urology. 175: 260-261. DOI: 10.1016/S0022-5347(18)33042-8 |
0.469 |
|
| 2005 |
Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, Lee SJ, Raikwar S, Gardner TA, Hutchins GD, VanderPutten D, Kao C, Jeng MH. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Molecular Cancer Therapeutics. 4: 1850-9. PMID 16373700 DOI: 10.1158/1535-7163.Mct-05-0167 |
0.347 |
|
| 2005 |
Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA, Gardner TA. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 1091-100. PMID 16169279 DOI: 10.1016/J.Ymthe.2005.07.690 |
0.502 |
|
| 2005 |
Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jiménez JA, Gardner TA, Jeng MH, Kao C. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Research. 65: 1941-51. PMID 15753394 DOI: 10.1158/0008-5472.Can-04-3666 |
0.547 |
|
| 2005 |
Jiménez JA, Kao C, Lee SJ, Jung C, Gardner TA. Gene therapy for prostate cancer Prostate Cancer: Basic Mechanisms and Therapeutic Approaches. 75-105. DOI: 10.1142/9789812569202_0004 |
0.375 |
|
| 2005 |
Li X, Zhang Y, Bae K, Stantz KM, Lee S, Jung C, Juan, Jemenez A, Jeng M, Kao C, Gardener TA. 819: Gene Therapy for Prostate Cancer by Controlling Adenovirus E1a and E4 Gene Expression with PSES Enhancer The Journal of Urology. 173: 222-222. DOI: 10.1016/S0022-5347(18)34988-7 |
0.451 |
|
| 2005 |
Li X, Zhang YP, Kim H, Bae K, Stantz KM, Lee S, Jung C, Jiménez JA, Gardner TA, Jeng M, Kao C. 1009. Gene Therapy for Prostate Cancer by Controlling Adenovirus E1A and E4 Gene Expression with PSES Enhancer Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.556 |
0.549 |
|
| 2004 |
Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1051-8. PMID 15564137 DOI: 10.1016/J.Ymthe.2004.08.028 |
0.521 |
|
| 2004 |
Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Research. 24: 2135-40. PMID 15330153 |
0.377 |
|
| 2004 |
Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 101: 83-9. PMID 15221992 DOI: 10.1002/Cncr.20327 |
0.408 |
|
| 2004 |
Lim HY, Ahn M, Chung HC, Gardner TA, Kao C, Lee SJ, Kim SJ. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Cancer Gene Therapy. 11: 532-8. PMID 15167900 DOI: 10.1038/Sj.Cgt.7700732 |
0.326 |
|
| 2004 |
Zheng QH, Gardner TA, Raikwar S, Kao C, Stone KL, Martinez TD, Mock BH, Fei X, Wang JQ, Hutchins GD. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorganic & Medicinal Chemistry. 12: 2887-93. PMID 15142549 DOI: 10.1016/J.Bmc.2004.03.051 |
0.374 |
|
| 2004 |
Shirakawa T, Gotoh A, Zhang Z, Kao C, Chung LW, Gardner TA. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer. Urology. 63: 613-8. PMID 15028478 DOI: 10.1016/J.Urology.2003.09.054 |
0.349 |
|
| 2004 |
Zeng G, Hu Z, Zhang S, Li L, Baldridge L, Kao C, Gardner TA, Koch MO, Ulbright TM, Eble JN, Cheng L. 1823: Epha2: A Novel Target for Prostate Cancer Treatment Journal of Urology. 171: 482-482. DOI: 10.1016/S0022-5347(18)39015-3 |
0.445 |
|
| 2004 |
Gardner TA, Raikwar SP, Lee S, Bunde PJ, Li X, Kao C. 616: AD-PSES-Trail: A Novel Prostate Specific Trail Over-Expressing Adenoviral Vector for Androgen Independent Prostate Cancer Gene Therapy Journal of Urology. 171: 164-164. DOI: 10.1016/S0022-5347(18)37878-9 |
0.492 |
|
| 2004 |
Raikwar SP, Gardner TA, Kao C. 1021. VP22 Mediates Tumor Vasculature Specific Targeting Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.966 |
0.525 |
|
| 2004 |
Raikwar SP, Kao C, Gardner TA. 966. Synergy between Angiostatin-Endostatin and Tie-2: A Novel Anti-Angiogenic Gene Therapy for Prostate Cancer Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.909 |
0.532 |
|
| 2004 |
Shirakawa T, Hinata N, Terao S, Shigemura K, Taniguch N, Fukushima K, Sugimoto K, Sugimura K, Matsuo M, Maeda S, Kamidono S, Kao C, Gardner TA, Chung LWK, Gotoh A. 604. Phase I/II clinical trial of Ad-OC-TK plus VAL for the patients with metastatic or local recurrent prostate cancer: initial experience in Japan Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.527 |
0.508 |
|
| 2003 |
Ou YC, Chen JT, Yang CR, Ko JL, Hsieh YS, Kao C. Expression of osteocalcin in prostate cancer before and after hormonal therapy. Anticancer Research. 23: 3807-11. PMID 14666681 |
0.359 |
|
| 2003 |
Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. The American Journal of Pathology. 163: 2271-6. PMID 14633601 DOI: 10.1016/S0002-9440(10)63584-5 |
0.461 |
|
| 2003 |
Li X, Cui Q, Kao C, Wang GJ, Balian G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone. 33: 652-9. PMID 14555271 DOI: 10.1016/S8756-3282(03)00239-4 |
0.328 |
|
| 2003 |
Lee SJ, Lee K, Yang X, Jung C, Gardner T, Kim HS, Jeng MH, Kao C. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen. Journal of Molecular Biology. 330: 749-60. PMID 12850144 DOI: 10.1016/S0022-2836(03)00640-5 |
0.378 |
|
| 2003 |
Wang C, Yeung F, Liu PC, Attar RM, Geng J, Chung LW, Gottardis M, Kao C. Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen. The Journal of Biological Chemistry. 278: 32423-30. PMID 12782640 DOI: 10.1074/Jbc.M207862200 |
0.414 |
|
| 2003 |
Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Human Gene Therapy. 14: 227-41. PMID 12639303 DOI: 10.1089/10430340360535788 |
0.516 |
|
| 2002 |
Gardner TA, Sloan J, Raikwar SP, Kao C. Prostate cancer gene therapy: past experiences and future promise. Cancer Metastasis Reviews. 21: 137-45. PMID 12465753 DOI: 10.1023/A:1020875925685 |
0.455 |
|
| 2002 |
Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L, Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 415-21. PMID 12231179 DOI: 10.1006/Mthe.2002.0682 |
0.501 |
|
| 2002 |
Zhang S, Zeng G, Kao C, Gardner T, Sweeney C, Yang NS, Eble JN, Cheng L. Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. The Prostate. 53: 69-76. PMID 12210482 DOI: 10.1002/Pros.10132 |
0.367 |
|
| 2002 |
Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, Koch MO, Eble JN, Cheng L. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer. 95: 296-300. PMID 12124829 DOI: 10.1002/Cncr.10674 |
0.364 |
|
| 2002 |
Cheon J, Moon DG, Cho HY, Park HS, Kim JJ, Gardner TA, Kao C. Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model. International Journal of Urology : Official Journal of the Japanese Urological Association. 9: 261-7. PMID 12060439 DOI: 10.1046/J.1442-2042.2002.00464.X |
0.386 |
|
| 2002 |
Hsieh CL, Yang L, Miao L, Yeung F, Kao C, Yang H, Zhau HE, Chung LW. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Research. 62: 3084-92. PMID 12036918 |
0.372 |
|
| 2002 |
Zhang S, Gu J, Yang NS, Kao C, Gardner TA, Eble JN, Cheng L. Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. The Prostate. 51: 286-92. PMID 11987157 DOI: 10.1002/Pros.10081 |
0.451 |
|
| 2002 |
Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. The Journal of Biological Chemistry. 277: 2468-76. PMID 11684680 DOI: 10.1074/Jbc.M105947200 |
0.47 |
|
| 2001 |
Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells International Journal of Cancer. 94: 282-289. PMID 11668510 DOI: 10.1002/Ijc.1453 |
0.342 |
|
| 2000 |
Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LWK. Tissue-specific promoters in gene therapy for the treatment of prostate cancer Molecular Urology. 4: 73-82. PMID 12006246 DOI: 10.1089/10915360050138620 |
0.527 |
|
| 2000 |
Shirakawa T, Gotoh A, Gardner TA, Kao C, Zhang ZJ, Matsubara S, Wada Y, Hinata N, Fujisawa M, Hanioka K, Matsuo M, Kamidono S. P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model Journal of Gene Medicine. 2: 426-432. PMID 11199263 DOI: 10.1002/1521-2254(200011/12)2:6<426::Aid-Jgm140>3.0.Co;2-2 |
0.455 |
|
| 2000 |
Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. The Journal of Biological Chemistry. 275: 40846-55. PMID 11006269 DOI: 10.1074/Jbc.M002755200 |
0.479 |
|
| 2000 |
Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Cluing LWK, Gardner TA. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis World Journal of Urology. 18: 102-110. PMID 10854144 DOI: 10.1007/S003450050181 |
0.498 |
|
| 1999 |
Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LWK, Kao C. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5- fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model Journal of Urology. 162: 949-954. PMID 10458414 DOI: 10.1097/00005392-199909010-00096 |
0.396 |
|
| 1999 |
Shirakawa T, Matsubara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S, Gardner TA, Wada Y, Ko S, Kao C. Molecular Therapy With Recombinant Wt-P53 Adenovirus For The Treatment Of Benign Prostatic Hyperplasia In Human Cells And Rat Experimental Models The Journal of Urology. 359. DOI: 10.1097/00005392-199904020-00440 |
0.44 |
|
| 1999 |
Cheon J, Kim HK, Shim GS, Koh SK, Ko S, Ou Y, Gardner TA, Kao C. ABLATION OF MURINE PROSTATE UTILIZING Ad-OC-TK/GCV TREATMENT: A POTENTIAL GENE THERAPY STRATEGY FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) The Journal of Urology. 305. DOI: 10.1097/00005392-199904020-00223 |
0.474 |
|
| 1999 |
Shirakawa T, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S, Gardner TA, Wada Y, Kao C. DEVELOPMENT OF HUMAN CHORIONIC GONADOTROPIN SUBUNIT beta (beta-hCG) PROMOTER-BASED TOXIC GENE THERAPY FOR TESTICULAR GERM CELL TUMOR The Journal of Urology. 183. DOI: 10.1097/00005392-199904010-00734 |
0.318 |
|
| 1999 |
Ou Y, Yeung F, Yang L, Kao C, Chung LWK, Gardner TA. Mn Promoter Activity In Renal Cell Carcinoma Cell Lines: A Potential For Tissue Restrictive Gene Therapy The Journal of Urology. 145. DOI: 10.1097/00005392-199904010-00582 |
0.358 |
|
| 1999 |
Ou Y, Gardner TA, Ko S, Zhau HE, Kao C, Chung LWK, Water D. Expression Of Osteocalcin In Canine Metastatic Prostate Cancer: A Ideal Prostate Cancer Animal Model For Osteocalcin Promoter-Based Toxic Gene Therapy The Journal of Urology. 131. DOI: 10.1097/00005392-199904010-00526 |
0.49 |
|
| 1999 |
Cheon J, Moon DG, Kim JJ, Kim HK, Koh SK, Ko S, Gardner TA, Kao C, Chung LWK. Improved Long-Term Survival Of Hosts Treated With Adenovirus-Mediated Suicide Gene Therapy In An Orthotopic Murine Bladder Tumor Model The Journal of Urology. 115. DOI: 10.1097/00005392-199904010-00463 |
0.35 |
|
| 1999 |
Kim SJ, Gardner TA, Ko S, Kao C, Balian G, Chung LWK. Enhancement Of Bystander Prostate Cancer Cell Killing By The Utilization Of Genetically Engineered Bone Stromal Cells That Confer Either Cytosine Deaminase Or Thymidine Kinase Gene The Journal of Urology. 58. DOI: 10.1097/00005392-199904010-00235 |
0.428 |
|
| 1998 |
Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. International Journal of Cancer. Journal International Du Cancer. 77: 887-94. PMID 9714059 DOI: 10.1002/(Sici)1097-0215(19980911)77:6<887::Aid-Ijc15>3.0.Co;2-Z |
0.487 |
|
| 1998 |
Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. The Journal of Urology. 160: 220-9. PMID 9628654 DOI: 10.1016/S0022-5347(01)63094-5 |
0.504 |
|
| 1998 |
Jeng MH, Kao C, Sivaraman L, Krnacik S, Chung LW, Medina D, Conneely OM, O'Malley BW. Reconstitution of estrogen-dependent transcriptional activation of an adenoviral target gene in select regions of the rat mammary gland. Endocrinology. 139: 2916-25. PMID 9607802 DOI: 10.1210/Endo.139.6.6073 |
0.312 |
|
| 1997 |
Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Human Gene Therapy. 7: 1683-91. PMID 8886839 DOI: 10.1089/Hum.1996.7.14-1683 |
0.531 |
|
| 1997 |
Gotoh A, Kao C, Ko S, Hamada K, Liu T, Chung LW. Cytotoxic Effects of Recombinant Adenovirus p53 and Cell Cycle Regulator Genes (p21 sup WAF1/CIP1 and p16 sup CDKN4) in Human Prostate Cancers Journal of Urology. 158: 636-641. DOI: 10.1016/S0022-5347(01)64574-9 |
0.47 |
|
| 1996 |
Zhau HYE, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK. Androgen-repressed phenotype in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America. 93: 15152-15157. PMID 8986779 DOI: 10.1073/Pnas.93.26.15152 |
0.487 |
|
| Show low-probability matches. |